دورية أكاديمية
أعرض في EDS

Pruritus in cutaneous graft-versus-host disease: A systematic review.

التفاصيل البيبلوغرافية
العنوان: Pruritus in cutaneous graft-versus-host disease: A systematic review.
المؤلفون: Zhu J; Department of Dermatology, University Hospital Basel, Basel, Switzerland., Navarini AA; Department of Dermatology, University Hospital Basel, Basel, Switzerland., Halter JP; Department of Haematology, University Hospital Basel, Basel, Switzerland., Mueller SM; Department of Dermatology, University Hospital Basel, Basel, Switzerland.
المصدر: Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2023 Jul; Vol. 37 (7), pp. 1276-1283. Date of Electronic Publication: 2023 Apr 05.
نوع المنشور: Systematic Review; Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 9216037 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-3083 (Electronic) Linking ISSN: 09269959 NLM ISO Abbreviation: J Eur Acad Dermatol Venereol Subsets: MEDLINE
أسماء مطبوعة: Publication: Oxford : Wiley-Blackwell
Original Publication: Amsterdam ; New York : Elsevier Science Publishers, c1992-
مواضيع طبية MeSH: Skin Diseases*/drug therapy , Graft vs Host Disease* , Hematopoietic Stem Cell Transplantation*, Humans ; Antipruritics/therapeutic use ; Quality of Life ; Pruritus/drug therapy
مستخلص: Pruritus is a common symptom of cutaneous graft-versus-host disease (GVHD) following haematopoietic stem cell transplantation (HSCT). However, little is known about its prevalence, pathophysiology, perceptual characteristics, impact on quality of life and response to antipruritic therapies. The aim of this review was to determine the current knowledge on pruritus in cutaneous GVHD. The review was conducted according to the Preferred Reporting Items for Systematic Review and Meta-Analyses statement. Of the 338 studies screened, 13 were included. The prevalence of pruritus in cutaneous GVHD was reported in three studies, ranging from 37.0% to 63.8%. Only four trials used pruritus assessment tools. There was little or no information on the intensity of pruritus, its qualitative perception, the location of pruritus and the impact of pruritus on quality of life. Antipruritic treatments for GVHD-associated pruritus were mentioned in five studies (38.5%), including topical ointments (steroids, tacrolimus and calcipotriene), broadband UVB, systemic antihistamines and oral ursodeoxycholic acid. In conclusion, pruritus in cutaneous GVHD appears to be common, but very little is known about the pathophysiology, impact on quality of life and effective treatment options. Basic research and controlled clinical trials are warranted to improve knowledge and management of this important issue.
(© 2023 European Academy of Dermatology and Venereology.)
References: Winkelmann RK, Muller SA. Pruritus. Annu Rev med. 1964;15:53-64.
Yosipovitch G, Bernhard JD. Clinical practice. Chronic pruritus. N Engl J Med. 2013;368:1625-34.
Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015;21:389-401.e381.
Nassereddine S, Rafei H, Elbahesh E, Tabbara I. Acute graft versus host disease: a comprehensive review. Anticancer Res. 2017;37:1547-55.
Saidu NEB, Bonini C, Dickinson A, Grce M, Inngjerdingen M, Koehl U, et al. New approaches for the treatment of chronic graft-versus-host disease: current status and future directions. Front Immunol. 2020;11:578314.
Lee SJ, Wolff D, Kitko C, Koreth J, Inamoto Y, Jagasia M, et al. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transplant. 2015;21:984-99.
Lee SJ. Classification systems for chronic graft-versus-host disease. Blood. 2017;129:30-7.
Zeiser R, Blazar BR. Acute graft-versus-host disease - biologic process, prevention, and therapy. N Engl J Med. 2017;377:2167-79.
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.
Klager S, Lacouture ME, Hannum M, Devlin SM, Maloy M, Pulitzer M, et al. Drugs as a frequent cause of acute rash in patients after CD34(+)-selected peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2019;25:2172-80.
Curtis LM, Grkovic L, Mitchell SA, Steinberg SM, Cowen EW, Datiles MB, et al. NIH response criteria measures are associated with important parameters of disease severity in patients with chronic GVHD. Bone Marrow Transplant. 2014;49:1513-20.
Knutsson ES, Bjork Y, Broman AK, Helstrom L, Nicklasson M, Brune M, et al. A prospective study of female genital chronic graft-versus-host disease symptoms, signs, diagnosis and treatment. Acta Obstet Gynecol Scand. 2018;97:1122-9.
Li K, Mu ZL, Chen X, Wen GD, Zhao Y, Zhang JZ. Atopic dermatitis-like graft-versus-host disease and lichen planus-like graft-versus-host disease: alterations in skin barrier function and related molecules. Chin Med J (Engl). 2017;130:1459-66.
Palmer J, Chai XY, Pidala J, Inamoto Y, Martin PJ, Storer B, et al. Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease. Blood. 2016;127:160-6.
Wallace G, Khandelwal P, Myers KC, Perentesis EMR, Lane A, Teusink-Cross A, et al. Prospective pilot trial of calcipotriene as a novel topical treatment for acute skin graft versus host disease. Bone Marrow Transplant. 2021;56:1441-4.
Duo LJ. Electrical needle therapy of uremic pruritus. Nephron. 1987;47:179-83.
National Institutes of Health, National Cancer Institute, U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. 2009 [cited 2022 Sep 15]. p 184. Available from: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.
Li K, Mu Z, Wen G, Zhao Y, Cong X, Zhang J. Increased regulatory T cells and eosinophils characterize atopic dermatitis-like graft-versus-host disease compared with lichen planus-like graft-versus-host disease. J Am Acad Dermatol. 2020;83:824-31.
Choi CJ, Nghiem P. Tacrolimus ointment in the treatment of chronic cutaneous graft-vs-host disease - a case series of 18 patients. Arch Dermatol. 2001;137:1202-6.
Enk CD, Elad S, Vexler A, Kapelushnik J, Gorodetsky R, Kirschbaum M. Chronic graft-versus-host disease treated with UVB phototherapy. Bone Marrow Transplant. 1998;22:1179-83.
Fried RH, Murakami CS, Fisher LD, Willson RA, Sullivan KM, McDonald GB. Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver. Ann Intern Med. 1992;116:624-9.
Arat M, Idilman R, Soydan EA, Soykan I, Erden E, Karayalçin S, et al. Ursodeoxycholic acid treatment in isolated chronic graft-vs.-host disease of the liver. Clin Transplant. 2005;19:798-803.
Castano G, Lyons CJ. Eyelid pruritus with intravenous morphine. J AAPOS. 1999;3:60.
Stander S, Weisshaar E, Mettang T, Szepietowski JC, Carstens E, Ikoma A, et al. Clinical classification of itch: a position paper of the International Forum for the Study of Itch. Acta Derm Venereol. 2007;87:291-4.
Stander S, Augustin M, Reich A, Blome C, Ebata T, Phan NQ, et al. Pruritus assessment in clinical trials: consensus recommendations from the International Forum for the Study of Itch (IFSI) Special Interest Group Scoring Itch in Clinical Trials. Acta Derm Venereol. 2013;93:509-14.
Handjani F, Saki N, Emad N, Hadibarhaghtalab M, Jafferany M. Psychodermatology in Iran: a survey on knowledge, awareness, and practice patterns in Iranian dermatologists. Dermatol Ther. 2020;33:e14009.
Reszke R, Szepietowski JC. Itch and psyche: Bilateral Associations. Acta Derm Venereol. 2020;100:adv00026.
Marks C, Stadler M, Hausermann P, Wolff D, Buchholz S, Stary G, et al. German-Austrian-Swiss Consensus Conference on clinical practice in chronic graft-versus-host disease (GVHD): guidance for supportive therapy of chronic cutaneous and musculoskeletal GVHD. Br J Dermatol. 2011;165:18-29.
Couriel D, Carpenter PA, Cutler C, Bolaños-Meade J, Treister NS, Gea-Banacloche J, et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group report. Biol Blood Marrow Transplant. 2006;12:375-96.
Carpenter PA, Kitko CL, Elad S, Flowers ME, Gea-Banacloche JC, Halter JP, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group report. Biol Blood Marrow Transplant. 2015;21:1167-87.
Legat FJ. The antipruritic effect of phototherapy. Front Med (Lausanne). 2018;5:333.
Legat FJ. Is there still a role for UV therapy in itch treatment? Exp Dermatol. 2019;28:1432-8.
Andersen YMF, Egeberg A, Balslev E, Jørgensen CLT, Szecsi PB, Stender S, et al. Filaggrin loss-of-function mutations, atopic dermatitis and risk of actinic keratosis: results from two cross-sectional studies. J Eur Acad Dermatol Venereol. 2017;31:1038-43.
Indra AK. Epidermal TSLP: a trigger factor for pathogenesis of atopic dermatitis. Expert Rev Proteomics. 2013;10:309-11.
Kim BE, Leung DY, Boguniewicz M, Howell MD. Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6. Clin Immunol. 2008;126:332-7.
Mollanazar NK, Smith PK, Yosipovitch G. Mediators of chronic pruritus in atopic dermatitis: getting the itch out? Clin Rev Allergy Immunol. 2016;51:263-92.
Weisshaar E, Szepietowski JC, Dalgard FJ, Garcovich S, Gieler U, Giménez-Arnau AM, et al. European S2k guideline on chronic pruritus. Acta Derm Venereol. 2019;99:469-506.
Kursewicz C, Fowler E, Rosen J, Castillo D, Chan Y, Nattkemper L, et al. Sex differences in the perception of itch and quality of life in patients with chronic pruritus in the United States. Itch. 2020;5:e41-1.
Schmid Y, Navarini A, Thomas ZM, Pfleiderer B, Krähenbühl S, Mueller SM. Sex differences in the pharmacology of itch therapies - a narrative review. Curr Opin Pharmacol. 2019;46:122-42.
Stander S, Stumpf A, Osada N, Wilp S, Chatzigeorgakidis E, Pfleiderer B. Gender differences in chronic pruritus: women present different morbidity, more scratch lesions and higher burden. Br J Dermatol. 2013;168:1273-80.
Sukul N, Karaboyas A, Csomor PA, Schaufler T, Wen W, Menzaghi F, et al. Self-reported pruritus and clinical, dialysis-related, and patient-reported outcomes in hemodialysis patients. Kidney Med. 2021;3:42-53.e41.
معلومات مُعتمدة: Gottfried und Julia Bangerter-Rhyner-Stiftung
المشرفين على المادة: 0 (Antipruritics)
تواريخ الأحداث: Date Created: 20230323 Date Completed: 20230614 Latest Revision: 20230614
رمز التحديث: 20240628
DOI: 10.1111/jdv.19057
PMID: 36950958
قاعدة البيانات: MEDLINE
الوصف
تدمد:1468-3083
DOI:10.1111/jdv.19057